Pre-made Capromab benchmark antibody (Radiolabelled antibody, anti-FOLH1/GCPII therapeutic antibody, Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP Antibody) for drug discovery and mechanism of action (MOA) research

Pre-made Capromab benchmark antibody (Radiolabelled antibody, anti-FOLH1/GCPII therapeutic antibody, Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Indium (111In) capromab pendetide (trade name Prostascint) is used to image the extent of prostate cancer.[1] Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide, a derivative of DTPA.[2] Pendetide acts as a chelating agent for the radionuclide indium-111. Following an intravenous injection of Prostascint, imaging is performed using single-photon emission computed tomography (SPECT).[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-771-1mg	1mg	3090
GMP-Bios-INN-771-10mg	10mg	Inquiry
GMP-Bios-INN-771-100mg	100mg	Inquiry
GMP-Bios-INN-771-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Capromab Biosimilar, Radiolabelled Antibody, Anti-FOLH1/GCPII Antibody: Anti-FGCP/FOLH/GCP2/NAALAD1/PSM/PSMA/mGCP therapeutic antibody
INN Name	Capromab
Target	FOLH1/GCPII
Format	Radiolabelled antibody
Derivation	Mus musculus
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	EUSA Pharma (Doylestown PA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0